FDAnews
www.fdanews.com/articles/206176-lumiradxs-c-reactive-protein-respiratory-disease-test-receives-ce-mark

LumiraDx’s C-Reactive Protein Respiratory Disease Test Receives CE Mark

January 14, 2022

UK-based LumiraDx has received a CE mark for its portable C-reactive protein (CRP) test, which is used to assess respiratory infections.

Significantly high CRP levels are found in patients with pneumonia, indicating the need for antibiotic treatment, whereas normal or low CRP levels suggest patients have viral or self-limiting infection that does not require antibiotics, the company said.

The fingerstick blood test runs on the LumiraDx Platform, which can be used at the patient’s side in primary and community care, and in hospital emergency care settings.

View today's stories